Skubitz A P, McCarthy J B, Charonis A S, Furcht L T
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455.
J Biol Chem. 1988 Apr 5;263(10):4861-8.
Monoclonal antibodies were utilized to localize novel heparin-binding domains of laminin. A solid-phase radioligand binding assay was designed such that [3H] heparin bound to laminin in a time- and concentration-dependent manner. Tritiated heparin binding to laminin was saturable and specific as determined by competition with unlabeled heparin, dextran sulfate, and dermatan sulfate. By Scatchard analysis, two distinct dissociation constants were calculated (Kd = 50 and 130 nM), suggesting the presence of at least two binding sites for heparin on laminin. Tritiated heparin bound to thrombin-resistant (600 kDa) and chymotrypsin-resistant (440 kDa) laminin fragments, both known to lack the terminal globular domain of the long arm. Sodium dodecyl sulfate-polyacrylamide gels of chymotrypsin- and thermolysin-digested laminin chromatographed on a heparin-Sepharose column showed multiple proteolytic fragments binding to the column. Monoclonal antibodies generated against laminin were tested for their ability to inhibit [3H]heparin binding to laminin. Four monoclonal antibodies significantly inhibited the binding of [3H]heparin to laminin in the range of 15-21% inhibition. Laminin-monoclonal antibody interactions examined by electron microscopy showed that one antibody reacted at the terminal globular domain of the long arm, domain Hep-1, while epitopes for two of these monoclonal antibodies were located on the lateral arms of laminin, domain Hep-2, and the fourth monoclonal antibody bound below the cross-region of laminin, domain Hep-3. When two monoclonal antibodies recognizing distinctly different regions of laminin were added concomitantly, the inhibition of [3H]heparin binding to laminin increased almost 2-fold. These results suggest that at least two novel heparin-binding domains of laminin may be located in domains distinct from the terminal globular domain of the long arm.
利用单克隆抗体定位层粘连蛋白新的肝素结合结构域。设计了一种固相放射性配体结合试验,使[3H]肝素以时间和浓度依赖的方式与层粘连蛋白结合。通过与未标记的肝素、硫酸葡聚糖和硫酸皮肤素竞争测定,氚标记的肝素与层粘连蛋白的结合具有饱和性和特异性。通过Scatchard分析,计算出两个不同的解离常数(Kd = 50和130 nM),表明层粘连蛋白上至少存在两个肝素结合位点。氚标记的肝素与已知缺乏长臂末端球状结构域的抗凝血酶(600 kDa)和抗胰凝乳蛋白酶(440 kDa)层粘连蛋白片段结合。在肝素-琼脂糖柱上进行层析的经胰凝乳蛋白酶和嗜热菌蛋白酶消化的层粘连蛋白的十二烷基硫酸钠-聚丙烯酰胺凝胶显示多个蛋白水解片段与该柱结合。测试了针对层粘连蛋白产生的单克隆抗体抑制[3H]肝素与层粘连蛋白结合的能力。四种单克隆抗体在15 - 21%的抑制范围内显著抑制[3H]肝素与层粘连蛋白的结合。通过电子显微镜检查的层粘连蛋白-单克隆抗体相互作用表明,一种抗体在长臂的末端球状结构域即Hep-1结构域发生反应,而其中两种单克隆抗体的表位位于层粘连蛋白的侧臂即Hep-2结构域,第四种单克隆抗体结合在层粘连蛋白的交叉区域下方即Hep-3结构域。当同时添加两种识别层粘连蛋白明显不同区域的单克隆抗体时,[3H]肝素与层粘连蛋白结合的抑制作用增加了近2倍。这些结果表明,层粘连蛋白至少两个新的肝素结合结构域可能位于与长臂末端球状结构域不同的结构域中。